United Therapeutics Corporation
Income Statement
| Line Item | FY2009 | FY2008 |
|---|---|---|
| Revenue | $358.9M | $281.5M |
| Cost of Revenue | $40.9M | $27.0M |
| Gross Profit | $316.8M | $254.5M |
| Gross Margin | 88.3% | 90.4% |
| Operating Expenses | ||
| Research & Development | $120.4M | $239.2M |
| SG&A Expense | $171.9M | $94.3M |
| Operating Income | $25.8M | $-82.1M |
| Operating Margin | 7.2% | -29.1% |
| Interest Expense | $12.9M | $11.4M |
| Pretax Income | $18.6M | — |
| Income Tax Expense | $-695.0K | $-34.4M |
| Net Income | $19.5M | $-49.3M |
| Net Margin | 5.4% | -17.5% |
| EPS (Basic) | $0.37 | $-1.08 |
| EPS (Diluted) | $0.35 | $-1.08 |
| Shares Outstanding (Basic) | 53.3M | 45.8M |
| Shares Outstanding (Diluted) | 56.1M | 45.8M |
| Dividends Per Share | — | — |